Incyte Corp.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Incyte Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Incyte Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Incyte Corp. is INCY:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Incyte Corp. has its primary listing on NASDAQ. You can trade Incyte Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Incyte Corp. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Incyte Corp. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Incyte Corp..